Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital

Dib, Jacobo; Alvarez, Bethseidy; Mendez, Liskie; Cruz, María

doi:10.1016/j.ajg.2013.09.001

Cited by 14 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this group performed subgroup analysis and identified that the standard triple regimen was statistically superior to a 7‐day levofloxacin‐based scheme in Asia, but levofloxacin‐based triple therapy was superior in European countries. A further small study from Venezuela, where clarithromycin resistance is high, reported 67% eradication with clarithromycin‐based therapy for 10 days compared with 95% for levofloxacin‐based triple therapy .…”

Section: Non‐bismuth Quadruple Sequential and Concomitant Therapymentioning

confidence: 99%

Treatment of Helicobacter pylori Infection 2014

et al. 2014

View full text Add to dashboard Cite

This review summarizes important studies regarding H.pylori therapy published from April 2013 to April 2014. The main themes that emerge are assessing the efficacy of standard triple therapy, as well as exploring new first-line treatments, predominantly optimized triple therapies and non-bismuth quadruple schemes. Regarding newer non-bismuth quadruple regimens, the compliance and tolerance seem to be similar for sequential and concomitant regimens. Notably, no study yet has demonstrated a clear statistical superiority for either, and a systematic review and meta-analysis may be warranted. Other studies examined the role of levofloxacin and bismuth based therapies in H. pylori eradication. The efficacy of bismuth as a second-line after sequential therapy was particularly noteworthy. Levofloxacin-based therapies also appear to be useful and versatile as part of different antibiotic combinations and in first-, second-, and third-line therapies. The emerging problem of quinolone resistance remains a worry. Individualized therapy, based on factors such as antimicrobial information, resistance data, and CYP2C19 metabolism, may well be the most notable future trend to emerge this year.

show abstract

Section: Non‐bismuth Quadruple Sequential and Concomitant Therapymentioning

confidence: 99%

Treatment of Helicobacter pylori Infection 2014

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Decreased eradication rates are due primarily to increased bacterial resistance to clarithromycin, indicating the need for new first-line treatments. [11][12][13][14] Bismuth is cytoprotective and antibacterial agent which has been safely used for three centuries. The addition of bismuth compounds to different antibiotic combinations have been reported to provide a favorable effect on eradication rates.…”

Section: Introductionmentioning

confidence: 99%

The impact of bismuth adding to rabeprazole, amoxicillin and clarithromycin on eradication rate of Helicobacter pylori

Sadrkabir

Tasouji

Sharghi

et al. 2020

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: High prevalence of Helicobacter pylori infection and induction of resistance as a result of consumption of antibiotics necessitates an ongoing effort for evaluation of new regimen to overcome this phenomenon. Intensive efforts are being made to identify such an optimal regimen, but there are many obstacles hindering the achievement of this goal. This study aimed to investigate the impact of adding bismuth to rabeprazole, amoxicillin and clarithromycin on rate of H. pylori eradication.Methods: In this randomized clinical trial, 60 patients with dyspepsia and positive gastric biopsy for H. pylori in endoscopy were recruited. The first group (A) received rabiprazole for 6 weeks, amoxicillin and clarithromycin for 2 weeks either with bismuth for 2 weeks and the second group (B) received rabiprazole for 6 weeks, amoxicillin and clarithromycin for 2 weeks either without bismuth. Four weeks after the treatment, the compliance and eradication were evaluated using stool antigen of helicobacter. The patients who could complete the therapeutic regimen were assigned for analysis.Results: H. pylori eradication rates were 70% and 56.6% in two groups A and B (with and without Bismuth), respectively and the difference was significant. There is a significant relationship between the studied groups and the results of fecal antigen of H. pylori.Conclusions: The bismuth had a significant effect on the success of eradication rate of H. pylori and its impact adding to the treatment regimen containing clarithromycin was effective on eradication success rate.

show abstract

“…Moreover, if a patient with dyspepsia undergoes endoscopy, H. pylori presence should be evaluated in gastric biopsies, with the intention of treating if present [9] . Triple therapy with a proton pump inhibitor (PPI), amoxicillin and clarithromycin is the most commonly used regimen for first line treatment of H.pylori infection and defined as standard protocol [10] .However, resistant types of H.pylori to this regimen had emerged [11] . levofloxacin-based triple therapy which consists of Levofloxacin 500mg once daily, PPI twice daily and amoxicillin 1gm twice daily for 14 days was a second line option [12] .…”

Section: Introductionmentioning

confidence: 99%

Levofloxacin Versus Clarithromycin-Based Therapy for Eradication of Helicobacter Pylori Infection: A Comparative Study

elshahat¹

2019

Zagazig University Medical Journal

View full text Add to dashboard Cite

Background: Helicobacter pylori (H.pylori) infection causes multiple upper gastrointestinal diseases but optimal therapeutic regimen which can eradicate infection in all the cases has not yet been defined. Antimicrobial resistance has decreased eradication rates for H.pylori infection worldwide. The aim of the present study was to compare between the efficacy and tolerability of levofloxacin versus Clarithromycin based triple therapy in eradication of H.pylori infection. Subjects and Methods: In this comparative cross sectional study, 142 patients with epigastric pain and dyspepsia and positive stool antigen test and only 35 of them were further confirmed by Rapid Urease Test during upper endoscopy (endoscopy was indicated) were enrolled. They were divided into 2 groups The first group (levofloxacin group) was treated with levofloxacin (500 mg daily) plus amoxicillin (1 gm twice a day) plus pantoprazol (40 mg twice daily) for 2 weeks. The second group (clarithromycin group) was treated with clarithromycin (500 mg twice a day) plus pantoprazol (40 mg twice daily) plus amoxicillin (1 gm twice a day) for 2 weeks. For treatment evaluation Stool antigen test was performed after four weeks after cessation of therapy. Results: H.pylori eradication was successful in 84.5% of the levofloxacin group and 69% of the clarithromycin group (P=0.001). The adverse effects were less frequent in levofloxacin-based than clarithromycin-based Ttiple therapy. Conclusion: Triple therapy with levofloxacin-based regimen has better efficacy than clarithromycin-based regimen.

show abstract

Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital

Cited by 14 publications

References 21 publications

Treatment of Helicobacter pylori Infection 2014

Treatment of Helicobacter pylori Infection 2014

The impact of bismuth adding to rabeprazole, amoxicillin and clarithromycin on eradication rate of Helicobacter pylori

Levofloxacin Versus Clarithromycin-Based Therapy for Eradication of Helicobacter Pylori Infection: A Comparative Study

Contact Info

Product

Resources

About